pelareorep + toripalimab

Pelareorep + LOQTORZI is an investigational combination regimen consisting of pelareorep, an intravenously delivered oncolytic virus immunotherapy, and LOQTORZI (toripalimab-tpzi), an FDA-approved programmed cell death protein 1 (PD-1) inhibitor. Developed under a clinical supply agreement between Oncolytics Biotech and Coherus BioSciences, the combination is designed to leverage complementary mechanisms of action to enhance antitumor immune responses. Pelareorep, an unmodified reovirus, selectively replicates in and lyses tumor cells with activated Ras pathways while activating Toll-like receptor 3 (TLR3) to stimulate innate and adaptive immune responses and promote tertiary lymphoid structure formation. Toripalimab blocks the PD-1 pathway, preventing tumor-mediated suppression of activated T cells. The combination is being evaluated in a planned clinical study for the second-line treatment of patients with squamous cell anal carcinoma (SCAC) who have progressed on first-line chemotherapy and checkpoint inhibition.